• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Nastech Pharmaceutical Company to Host Webinar on Its Strategy for Development of RNAi Therapeutics for Treatment of Influenza

Posted on: Monday, 6 August 2007, 09:19 CDT

BOTHELL, Wash., Aug. 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. will host a Webinar to discuss the Company's novel approach for the development of small interfering RNA (siRNA) therapeutics for treatment of influenza. Details follow:

What: Webinar discussing the approach of using siRNAs that target conserved regions of the influenza virus as a potential treatment of both pandemic and seasonal influenza. The webinar will provide information on Nastech's strategy of using siRNAs as a mechanism to inhibit viral replication, targets for treating influenza, process of screening and selecting active siRNAs, and technology for enhancing delivery of siRNAs to achieve a therapeutic effect. The Webinar will also discuss the ongoing work that is being conducted under a Cooperative Research and Development Agreement with the Center for Disease Control and Prevention evaluating Nastech's siRNAs and delivery technology across multiple influenza virus strains. When: Friday, August 10, 2007, from 8:00-9:00 a.m. Eastern Time. How: Live over the Internet at http://www.nastech.com/. Please connect to the Webinar via Nastech's website several minutes prior to the start of the live conference call to ensure adequate time for any software download that may be necessary. You may also listen to the live event and ask questions by phone. U.S. callers should dial 800-561-2693 and international callers should dial 617-614-3523. The passcode is 12673346. To listen to a replay of the event by telephone, U.S. callers should dial 888-286- 8010 and international callers should dial 617-801-6888. The passcode for the telephonic replay is 65741778. If you are unable to participate during the live RNAi Webinar webcast, an archive and replay will be available for 30 days via Nastech's website at http://www.nastech.com/. About RNA Interference (RNAi)

RNA interference, or RNAi, is a cellular mechanism that can be used to turn off the production of a protein. In the case of a siRNA directed against influenza, the target is one or more proteins critical for viral replication. If siRNAs are successful at turning off the production of such proteins, the spread of infection would be prevented or slowed. Nastech's siRNA research and development programs seek to develop safe and effective therapeutics by identifying key protein targets, designing the siRNA that will turn off the production of the targeted proteins, and developing a formulation for the delivery of this potential new class of therapeutics.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com/.

Nastech Forward-Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Contacts: Nastech Ed Bell Director, Investor Relations (425) 908-3639 ir@nastech.com Russo Partners, LLC Matthew Haines (Investors/Media) (212) 845-4235

Nastech Pharmaceutical Company Inc.

CONTACT: Ed Bell, Director, Investor Relations of Nastech,+1-425-908-3639, ir@nastech.com; or Investors-Media, Matthew Haines of RussoPartners, LLC, +1-212-845-4235

Web site: http://www.nastech.com/

Source: PRNewswire-FirstCall

More News in this Category